Indraprastha Medical Corporation share price today

Indraprastha Medical Corporation Ltd's share price was ₹330.20 at the close on 6 November 2026. It has been falling for 41 weeks. That is 13.2% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹300 and ₹548, and at that close it sat 12% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Indraprastha Medical Corporation Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 16 weeks running.

Over the last 11 years the share price moved +560% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 17 July 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: revenue up on a year earlier for 12 quarters in a row (every quarter we can compare), profit up on a year earlier for 12 quarters in a row (every quarter we can compare) and highest quarterly revenue in 16 quarters.

1. Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare)

   In the September 2026 quarter revenue was ₹413 crore, +8.4% on a year earlier.

2. Profit up on a year earlier for 12 quarters in a row (every quarter we can compare)

   In the September 2026 quarter profit was ₹54 crore, +10.2% on a year earlier.

3. Highest quarterly revenue in 16 quarters

   Revenue of ₹413 crore in the September 2026 quarter is the highest of the last 16 quarters.

For July to September 2026 (the quarter ended 30 September 2026), Indraprastha Medical Corporation reported revenue of ₹413 crore, up 8.4% from ₹381 crore a year earlier, and a profit of ₹54.0 crore, up 10.2% from ₹49.0 crore.

Indraprastha Medical Corporation results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Indraprastha Medical Corporation closed at ₹330.20 on 6 November 2026, down 46.7% from ₹619.90 a year earlier (7 November 2025) and up 343.2% over five years. Its highest weekly close since March 2016 was ₹619.90 on 7 November 2025.

Indraprastha Medical Corporation share price: then and now

Weekly closing prices. Each change is the move from that price to the 6 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

560 weekly closes from 11 March 2016 to 6 November 2026.

6 Nov 2026: Indraprastha Medical Corporation closed at ₹330.20, up 8.0% on the week and up 0.3% on the month. Results for July to September 2026: Revenue up 8.4% and profit up 10.2% on a year earlier.

Earlier

• 18 Sep 2026: ex-date for a dividend of ₹4 a share.

Indraprastha Medical Corporation paid ₹4 a share in regular dividends in the 12 months to 7 November 2026 (1 payment), a yield of 1.21% at the ₹330.20 close on 6 November 2026. The last was a dividend of ₹4 a share, ex-date 18 September 2026.

Indraprastha Medical Corporation dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Yes. Indraprastha Medical Corporation Ltd paid out 20% of its profit as dividends in FY26, and it paid a dividend in 11 of its last 13 reported years.

From the NSE corporate-actions record, read 7 November 2026.

Indraprastha Medical Corporation is on one of our India lists: 52 week high & low.

Indraprastha Medical Corporation Ltd earned ₹54.0 Cr of net profit in the Sep 2026 quarter, +10.2% on the same quarter a year earlier. That is the 12th quarter in a row of profit growth. Full-year FY26 profit was ₹184 Cr. Over 10 years profit has grown 22.6% a year on average. That is 13.1% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹49.0 Cr.

For the full year, FY26 profit was ₹184 Cr (+14.3% on the year before).

Why profit moved: revenue changed +8.4% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +11.6% and revenue +10.8%. Profit and revenue are moving at about the same pace.

Indraprastha Medical Corporation Ltd reported ₹413 Cr of revenue in the Sep 2026 quarter, +8.4% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 7.0% a year on average. The last full year, FY26, came in at ₹1,483 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹1,556 Cr.

FY26 revenue was ₹1,483 Cr, +9.4% on the year before.

Recent pace: the last four quarters grew +10.8% on average, against 7.0% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +10.7%, against +8.6% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +10.9%, against +14.6% a year (rolling over).

Indraprastha Medical Corporation Ltd's operating margin was 19.0% in the Sep 2026 quarter, about the same as the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 7.0% and 18.0%. The latest quarter is above every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

In the latest quarter it moved +0.0 percentage points on the same quarter a year ago.

Why the margin moved: operating margin changed +0.0 percentage points on the year while gross margin changed +0.9 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

Over the last 3 years, 112% of Indraprastha Medical Corporation Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹167 Cr of operating cash against ₹184 Cr of profit. After ₹51.0 Cr of spending on assets, ₹116 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 112% of profit came in as cash: the cash cycle got 12 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: the bigger use of cash is spending on new assets, at 1.7× depreciation over three years. The next section checks what that spending is building.

Indraprastha Medical Corporation Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 28 days in FY26, down from 40 days in FY21. It spent ₹218 Cr on assets over the last 3 years. Customers take 28 days to pay, and stock sits for 11 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹1,483 Cr, each day of that cycle ties up about ₹4.1 Cr, so roughly ₹114 Cr is tied up in the business at any time.

FY26: customers took 28 days to pay and stock sat for 11 days, about 0.4 months of sales sitting as stock, for a full cycle of 28 days, shorter than FY21's 40.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 11 days. Customers pay about 28 days after that. Suppliers are paid at 182 days. Together that makes the 28-day cycle.

Spending on assets: ₹218 Cr over the last 3 years, against ₹128 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹3.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Indraprastha Medical Corporation Ltd's P/E is 15.8×, in the middle of its own history: higher than 39% of past readings. Its usual P/E (the middle reading) is 18.2×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.